Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expect... ( SAN DIEGO April 9 2008 /- Favrill...)

HOME >> MEDICINE >> TECHNOLOGY

Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June

Date:4/9/2008

SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it has reached the data cutoff date for the Company's Phase 3 registration trial of Specifid(TM) (mitumprotimut-T, formerly FavId(R)) following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed) according to investigator determination. Final analysis will be based on a central radiology assessment of the patients' CT scans. Unblinding of the data is expected to occur in June 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

Median follow-up for ongoing patients is 31 months from randomization (range 21 to 41 months), or approximately 34 months from the initiation of Rituxan treatment (range 24 to 44 months). Based on the protocol's assumptions, this range of follow-up would provide sufficient power to detect a significant difference between the two arms for time to progression (TTP), the primary endpoint in the trial.

"We believe the design and execution of this registration trial have positioned us well for success," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "Based on the status of patients at data cutoff and our assumptions about the behavior of the control arm in this trial, we are very encouraged that the upcoming analysis will provide an outcome which is both clinically and statistically significant. Our clinical and biometrics
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
2. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Medarex Announces Ipilimumab Program Continues to Move Forward
7. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
8. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
9. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
10. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update

Post Your Comments:

(Date:5/20/2013)... LONDON , BERLIN and ... -- Arthroscopy Devices Market to 2018 ... Minimally Invasive Procedures to Drive Future Growth" looks at ... the six arthroscopy device market segments: arthroscopes, arthroscopy shavers, ... frequency systems, and arthroscopy visualization systems. The report provides ...

(Date:5/20/2013)... 2013 Neuralstem, Inc. (NYSE MKT: CUR) today reported ... principal investigator, presented updated Phase I data from its ... the treatment of amyotrophic lateral sclerosis (ALS or ... diabetes special medical symposium in Bucharest, Romania ... Therapeutic Advances in Stem Cell Therapy," Dr. Feldman outlined ...

(Date:5/20/2013)... , May 20, 2013 With herbal ... resource available from the U.S. Pharmacopeial Convention (USP) will ... quality of the herbal ingredients used in these products. ... included in the new Herbal Medicines Compendium ... worldwide at hmc.usp.org . HMC ...

Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2 Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3 Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4 Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2 Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3 Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4 New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2 New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3

[0] Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth [0] Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania [0] New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines

... Reportlinker.com announces that a new market research report ... Nephrology and Urology Devices Market Outlook to 2017 ... and Urology Devices Market Outlook to 2017 ... Nephrology and Urology Devices Market Outlook to 2017" provides ...

... Reportlinker.com announces that a new market research ... Continuous Glucose Monitoring (CGM) Systems ... Market Forecasts to 2016 ... Monitoring (CGM) Systems - Global Pipeline Analysis, ...

Reportlinker Adds Europe Nephrology and Urology Devices Market Outlook to 2017 Reportlinker Adds Continuous Glucose Monitoring (CGM) Systems - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

(Date:5/20/2013)... May 2013 While Huntington,s disease (HD) is ... new disease-modifying therapies in development may slow or ... research depends upon the identification of reliable and ... and these biomarkers may eventually be used as ... especially helpful to monitor changes during the time ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 ... adult allogeneic stem cell manufacturing, research and development, ... of Medicine and Director of Interventional Cardiology Research ... join the Scientific and Medical Advisory Board for ... of Pennsylvania, Dr. Wilensky divides his time between ...

(Date:5/20/2013)... of the much-anticipated Second Edition of The Biology of ... Edition has been hailed as an incomparable classic. Thoroughly ... fast-growing field of cancer biology, The Biology of Cancer, ... by students, instructors, researchers, and clinicians around the world. ... students studying the molecular and cellular bases of cancer ...

(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Boys who are ... likely to become obese adults as those who didn,t ... 30-year study shows. Researchers found that men with ... (BMI) and obesity, even if they no longer had ... well-off or poor, they tended toward obesity. "The ...

(Date:5/20/2013)... NY (PRWEB) May 20, 2013 In ... of the numerous scientific accomplishments achieved at The ... group of female scientists, Advancing Women in Science ... breakfast on May 17. Scientists, educators, business and ... celebrate excellence and achievements of women in science. ...

Breaking Medicine News(10 mins):Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2 Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3 Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 2 Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 3 Health News:'The Biology of Cancer' by Robert A. Weinberg 2 Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2 Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3 Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2 Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3

[0] Leading researchers report on the elusive search for biomarkers in Huntington's disease [0] Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board [0] 'The Biology of Cancer' by Robert A. Weinberg [0] ADHD in Childhood May Raise Risk for Obesity in Adulthood [0] North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week

... can do a lot to keep kids safe, experts say, , ... to be), youngsters are probably going to be spending less ... doing cannonballs. , It,s all fun and games -- until someone ... warn child safety experts. , Though many injuries amount to little ...

... Invited to Attend , , NEW ORLEANS, June 6 ... New Orleans for the 2009 Catholic Health Assembly, "In Our ... , The assembly, hosted by the Catholic Health Association of ... Catholic health care leaders from across the nation. They come ...

... ... Low Vision Conditions , ... Beach, CA (PRWEB) June 6, 2009 -- Enhanced Vision , America,s leading manufacturer of ... VISION 5K Run & Walk in Boston, MA this Saturday, June 7th. The unique event ...

... , - These acquisitions reinforce Genomma Lab,s presence in the cosmetics ... lotions and perfumes segments , , - Genomma Lab continues ... place in June 2008 , , ... C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of ...

... study found diabetes drug didn,t increase chances of heart disease, ... drug Avandia significantly raises the risk of both heart failure ... for either cardiovascular disease or death, new research has found. ... risk of death, said the authors of the much-anticipated RECORD ...

... June 5 NxStage Medical, Inc. (Nasdaq: ... today announced it has completed the closing of its ... alliance partner, Asahi Kasei Kuraray Medical. The Company used ... its entire debt obligation, including prepayment and other transaction ...

Cached Medicine News:Health News:Summer Fun Need Not Be Hazardous 2 Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 2 Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 3 Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 2 Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 3 Health News:Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns 2 Health News:Avandia Raises Risk of Heart Failure, Fractures 2 Health News:Avandia Raises Risk of Heart Failure, Fractures 3 Health News:Avandia Raises Risk of Heart Failure, Fractures 4 Health News:NxStage Announces Closing of $40 Million Debt Financing with Asahi Kasei Kuraray Medical 2

Summer Fun Need Not Be Hazardous 2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns Avandia Raises Risk of Heart Failure, Fractures NxStage Announces Closing of $40 Million Debt Financing with Asahi Kasei Kuraray Medical

Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....

Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....

Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left. Most popular size or model....

Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....

Medicine Products:

Scleral Plug Forceps Subretinal Forcep Black Long Jameson Muscle Forceps - Left Trouan Superior Rectus Forceps